Company intelligence / Profile preview
Oncternal Therapeutics
San Diego, California, United Statesoncternal.com ↗
- Ownership
- Public · ONCT
- Employees
- ~30
- Development stage
- Phase 1
01
Overview
The company discontinued all clinical trials on September 12, 2024, after disappointing data and a patient death in the ONCT-808 trial. ONCT-808 had shown antitumor activity at all dose levels tested with a complete metabolic response lasting 8 months, but one patient died from complications of shock at the highest dose tested. ONCT-534 failed to show meaningful disease improvements in an interim Phase 1/2 analysis.
- Therapeutic areas
- Oncology
- Modalities
- Monoclonal antibodiesCAR-T cell therapySmall moleculesDual-Action Androgen Receptor Inhibitors (DAARI)
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
Beyond the preview
Go deeper on Oncternal Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Oncternal Therapeutics.